Abstract
Public summary•BRD4:NUTM1 is the fusion oncogene driver in ∼70% of NUT carcinomas.•NUT IHC is recommended as an initial screening for malignant tumors exhibiting poorly differentiated phenotype.•Existing chemotherapy regimens and BET inhibitors have limited efficacy in NUT carcinoma.•For patients with advanced NUT carcinoma, rational clinical trial combinations should be considered.
| Original language | English (US) |
|---|---|
| Article number | 101068 |
| Journal | Innovation |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 5 2026 |
Bibliographical note
Publisher Copyright:© 2025 The Author(s). Published by Elsevier Inc. on behalf of Youth Innovation Co., Ltd. This is an open access article under the CC BY-NC-ND license. http://creativecommons.org/licenses/by-nc-nd/4.0/
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Clinical Medicine
- NUT carcinoma
- diagnosis
- guideline
- treatment
Fingerprint
Dive into the research topics of 'International guidelines on the diagnosis and treatment of NUT carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS